Iovance Biotherapeutics, Inc.
$3.78
▼
-0.58%
2026-04-21 07:34:00
www.iovance.com
NGM: IOVA
Explore Iovance Biotherapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.56 B
Current Price
$3.78
52W High / Low
$5.63 / $1.64
Stock P/E
—
Book Value
$1.7
Dividend Yield
—
ROCE
-51.39%
ROE
-55.5%
Face Value
—
EPS
$-1.09
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
975
Beta
0.76
Debt / Equity
7.08
Current Ratio
3.2
Quick Ratio
2.83
Forward P/E
-15.63
Price / Sales
5.78
Enterprise Value
$1.28 B
EV / EBITDA
-3.52
EV / Revenue
4.84
Rating
None
Target Price
$9
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Tvardi Therapeutics, Inc. | $3.22 | — | $30.72 M | — | -127.18% | -2.38% | $43.65 / $2.75 | $2.23 |
| 2. | Cabaletta Bio, Inc. | $3.31 | — | $382.95 M | — | -149.87% | -1.27% | $3.78 / $1.06 | $1.11 |
| 3. | Turn Therapeutics Inc. | $3.38 | — | $103.07 M | — | -134.02% | -1.42% | $26.5 / $2.57 | $0.02 |
| 4. | Monte Rosa Therapeutics, Inc. | $19.81 | — | $1.58 B | — | -14.1% | -16.94% | $25.77 / $3.51 | $3.56 |
| 5. | Corvus Pharmaceuticals, Inc. | $15.54 | — | $1.31 B | — | -69.6% | -32.6% | $26.95 / $3.11 | $0.82 |
| 6. | ProKidney Corp. | $2.1 | — | $634.02 M | — | -54.13% | -43.17% | $7.13 / $0.54 | $-7.13 |
| 7. | Artelo Biosciences, Inc. | $4.53 | — | $3.96 M | — | 917.46% | -16.25% | $85.8 / $2.96 | $-1.89 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 86.77 M | 67.45 M | 59.95 M | 49.32 M | 73.69 M | — |
| Operating Profit | -73.46 M | -89.76 M | -113.77 M | -121.22 M | -86.58 M | — |
| Net Profit | -71.9 M | -91.25 M | -111.66 M | -116.16 M | -78.56 M | — |
| EPS in Rs | -0.17 | -0.22 | -0.27 | -0.28 | -0.19 | -0.28 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 263.5 M | 164.07 M | 1.19 M | 0 M |
| Operating Profit | -398.21 M | -395.28 M | -460.56 M | -398.88 M |
| Net Profit | -390.98 M | -372.18 M | -444.04 M | -395.89 M |
| EPS in Rs | -0.95 | -0.9 | -1.08 | -0.96 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 913.17 M | 910.43 M | 780.35 M | 663.98 M |
| Total Liabilities | 214.59 M | 200.02 M | 195.74 M | 164.34 M |
| Equity | 698.58 M | 710.4 M | 584.61 M | 499.64 M |
| Current Assets | 442.69 M | 457.02 M | 307.85 M | 479.12 M |
| Current Liabilities | 138.36 M | 122.34 M | 110.31 M | 91.48 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -302.41 M | -352.98 M | -361.82 M | -292.76 M |
| Investing CF | 47.5 M | -96.41 M | -155.24 M | 256.45 M |
| Financing CF | 300.77 M | 390.66 M | 462.96 M | 190.15 M |
| Free CF | -336.24 M | -364.05 M | -384.11 M | -313.18 M |
| Capex | -33.84 M | -11.07 M | -22.29 M | -20.43 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 13698.99% | — | — | — |
| Earnings Growth % | 16.18% | -12.16% | — | — |
| Profit Margin % | -226.84% | -37345.42% | — | — |
| Operating Margin % | -240.92% | -38734.99% | — | — |
| Gross Margin % | 43.17% | 13.12% | — | — |
| EBITDA Margin % | -211.62% | -35948.86% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.